Study on Triarco’s Aminogen® Supports Safety of the Branded Enzyme Matrix
Wayne, NJ – September 17, 2012 – A double-blind, randomized clinical study published in the journal Food Digestion investigated the effects of adding Triarco Industries’ Aminogen® to whey protein and found the patented enzyme did not adversely affect clinical measures of cardiovascular, metabolic or renal-hepatic safety.
“While Triarco conducted pre-clinical toxicity research on Aminogen® years ago, and our previous clinical study included basic safety measures as part of good study design, we decided to take safety one step further,” said Triarco President Rodger Rohde Jr. “What makes this study even more valuable is that this is the first published clinical study we know of that focuses on clinical safety measures for fungal proteases taken daily.”
In the study, 40 healthy, active men ages 18-45 maintaining a regimen of resistance training were divided into two groups and received either 50 grams of whey protein or 50 grams of protein with 1.5 grams of Aminogen® twice a day for 30 days. Neither the subjects nor the experimenters were aware which group had received the patented enzyme.
In addition to finding no adverse effects on clinical measures of safety, the study also found that the group of subjects taking whey protein without Aminogen® experienced a significant increase in total and LDL cholesterol while the group taking Aminogen® did not.
Aminogen® was shown in a previous clinical study published in the Journal of the International Society of Sports Nutrition to triple the rate of amino acid absorption resulting in a 100 percent increase in amino acid levels, a 250 percent increase in key amino acid levels and a 32 percent increase in nitrogen retention. No adverse advents were reported.
Aminogen is self-affirmed GRAS and Kosher certified, and can be found in select protein powders, sports nutrition and weight maintenance supplements.